HU
$0.41
+0.00
(+0.46%)
As of Oct 22, 2026, 9:29 PM EDT · cached
Price history
Humacyte Inc (HUMA) is trading up at $0.41 (+0.46%), as of the latest quote. It operates in the Health Care sector.
Humacyte Inc revenue & net income history (FY2020–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $0 | $2.04M |
| Gross profit | — | — | — | — | $0 | −$7.66M |
| Gross margin | — | — | — | — | — | −376.1% |
| Operating income | −$64.6M | −$81.2M | −$84.6M | −$100.0M | −$114.4M | −$108.1M |
| Operating margin | — | — | — | — | — | −5306.0% |
| Net income | −$66.5M | −$26.5M | −$12.0M | −$110.8M | −$148.7M | −$40.8M |
| Net margin | — | — | — | — | — | −2003.6% |
| EPS (diluted) | −$11.54 | −$0.66 | −$0.12 | −$1.07 | −$1.26 | −$0.26 |
| Balance sheet | ||||||
| Cash and equivalents | $39.9M | $217.5M | $149.8M | $80.4M | $44.9M | $50.5M |
| Total assets | $106.7M | $286.5M | $204.3M | $128.2M | $137.9M | $116.4M |
| Total liabilities | $36.0M | $164.4M | $87.4M | $114.7M | $190.5M | $113.3M |
| Long-term debt | — | $30.0M | — | — | $0 | $35.4M |
| Shareholders' equity | −$350.3M | $122.2M | $116.9M | $13.5M | −$52.7M | $3.11M |
| Cash flow | ||||||
| Operating cash flow | −$55.6M | −$81.2M | −$71.1M | −$73.3M | −$98.1M | −$105.0M |
| Capital expenditure | $318.0K | $220.0K | $1.05M | $2.28M | $1.57M | $884.0K |
| Free cash flow | −$55.9M | −$81.4M | −$72.2M | −$75.6M | −$99.7M | −$105.9M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $517.0K | $301.0K | $753.0K | $467.0K | $495.0K | $406.0K |
| Growth (year over year) | — | — | — | — | — | — | −4.3% | +34.9% |
| Gross profit | $0 | — | $370.0K | $88.0K | $493.0K | −$8.62M | −$1.54M | −$825.0K |
| Gross margin | — | — | 71.6% | 29.2% | 65.5% | −1844.8% | −311.7% | −203.2% |
| Operating income | −$30.2M | — | −$23.2M | −$29.7M | −$24.4M | −$30.8M | −$28.9M | −$27.0M |
| Operating margin | — | — | −4484.3% | −9876.1% | −3239.0% | −6603.0% | −5845.5% | −6649.3% |
| Net income | −$39.2M | — | $39.1M | −$37.7M | −$17.5M | −$24.8M | −$17.6M | −$36.8M |
| Net margin | — | — | 7570.4% | −12511.0% | −2325.4% | −5311.3% | −3559.4% | −9064.5% |
| EPS (diluted) | −$0.33 | — | $0.28 | −$0.24 | −$0.11 | −$0.19 | −$0.09 | −$0.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $20.6M | $44.9M | $62.8M | $38.0M | $19.5M | $50.5M | $48.5M | $79.9M |
| Total assets | $114.8M | $137.9M | $162.6M | $138.8M | $91.5M | $116.4M | $110.6M | $138.1M |
| Total liabilities | $178.5M | $190.5M | $126.5M | $134.7M | $96.3M | $113.3M | $98.9M | $106.8M |
| Long-term debt | — | $0 | — | — | — | $35.4M | $35.9M | $36.3M |
| Shareholders' equity | −$63.7M | −$52.7M | $36.0M | $4.05M | −$4.75M | $3.11M | $11.6M | $31.3M |
| Cash flow | ||||||||
| Operating cash flow | −$22.9M | — | −$28.6M | −$26.4M | −$23.9M | −$26.1M | −$25.1M | −$22.1M |
| Capital expenditure | $934.0K | — | $228.0K | $568.0K | $49.0K | $39.0K | $175.0K | $104.0K |
| Free cash flow | −$23.8M | — | −$28.8M | −$27.0M | −$24.0M | −$26.2M | −$25.3M | −$22.2M |
From Humacyte Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Humacyte Inc
- Headquarters
- Durham, North Carolina From SEC filings, Oct 2026
Recent News (2)
-
Humacyte stock gains ordering hospitals, H.C. Wainwright reiterates Buy
Humacyte stock gains ordering hospitals, H.C. Wainwright reiterates Buy
-
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 - Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International